Otsuka and Transcend Therapeutics have announced an agreement under which Otsuka, through its wholly owned subsidiary Otsuka America, will fully acquire Transcend.
The acquisition is expected to be completed in the second quarter of 2026, subject to the fulfilment of customary closing conditions and required procedures.
Under the terms of the agreement, Otsuka will pay US$ 700 million to Transcend shareholders upon closing of the acquisition, and up to USD 525 million in additional contingent consideration based on future sales milestones related to assets in development, for a total potential consideration of USD $1.225 billion.
Transcend, founded in 2021, is a clinical stage biotechnology company developing rapid-acting treatments for neuropsychiatric diseases.
TSND-201 (methylone), which the company is developing, is a rapid-acting neuroplastogen — an agent that induces rapid and durable neural plasticity in the brain — and is being advanced as a potential treatment for post-traumatic stress disorder (PTSD) and other psychiatric conditions.
In the United States, more than 13 million individuals are estimated to be affected by PTSD each year, yet no new treatments have been approved for 25 years, underscoring the significant unmet medical need.
Recent research has demonstrated that changes in neuroplasticity in the brain are deeply involved in both the onset and persistence of PTSD symptoms.
Neuroplasticity, the brain’s ability to reorganise neural circuits, supports memory formation and emotional regulation. In PTSD, alterations in fear-related pathways impair the ability to relearn safety (‘overwriting fear’), driving growing interest in interventions that restore or enhance neuroplasticity.
TSND-201 (methylone) acts on monoamine transporters in the brain—including those for serotonin, norepinephrine, and dopamine. By promoting monoamine release, it increases monoamine concentrations within the synaptic cleft, resulting in rapid and sustained enhancement of neuroplasticity.
Importantly, TSND-201 does not act on the serotonin 5-HT2A receptor, which mediates hallucinogenic effects, and is therefore considered a non-hallucinogenic compound.
Transcend is also conducting research and development on novel prodrugs—classified as new chemical entities—to further improve the balance of efficacy, safety, and tolerability of TSND‑201.
The company has selected a development candidate and is currently performing non‑clinical studies in preparation for an Investigational New Drug application to the US Food and Drug Administration (FDA).
TSND‑201 demonstrated favourable results in the phase 2 clinical trial Impact‑1, which enrolled adults with PTSD, and study findings were published in JAMA Psychiatry in February.
Due to its rapid onset of activity and robust effects, TSND‑201 was granted Breakthrough Therapy designation by the FDA in July 2025. Transcend met with the FDA in September 2025, to discuss company plans to expedite the development of TSND-201 and confirm the design of the phase 3 study. Patient recruitment for the phase 3 trial is underway in the US.